Diasorin SpAWBO:DIAS +0.43%74 Forward PE Ratio is 18.29 as of Jul. 07, 2026. GuruFocus rates WBO:DIAS with a GF Score™ of 74/100 and a GF Value™ of €90.10 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 87 Medical Diagnostics & Research companies, Diasorin SpA ranks better than 63.22% on this metric.
Diasorin SpA's Forward PE Ratio for today is 18.29.
Diasorin SpA (WBO:DIAS) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Diasorin SpA Forward PE Ratio Related Terms
Diasorin SpA Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Diasorin SpA's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diasorin SpA Forward PE Ratio Chart
Diasorin SpA Annual Data
Trend
2020-12
2021-12
2024-12
2025-12
Forward PE Ratio
32.57
29.07
24.26
16.21
Diasorin SpA Quarterly Data
2020-09
2020-12
2021-03
2021-06
2021-09
2021-12
2022-03
2022-06
2022-09
2024-09
2024-12
2025-03
2025-06
2025-09
2025-12
2026-03
Forward PE Ratio
36.36
32.57
26.60
31.25
37.17
29.07
23.58
24.57
30.67
23.04
24.26
22.45
23.70
15.97
16.21
14.68
WBO:DIAS vs TMO, DHR, IDXX: Forward PE Ratio Comparison
For the Diagnostics & Research subindustry, Diasorin SpA's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diasorin SpA Forward PE Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Diasorin SpA's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Diasorin SpA's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Diasorin SpA (WBO:DIAS) has a Forward PE Ratio of 18.29 as of Jul. 07, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Diasorin SpA and its competitors. According to the industry distribution chart, Diasorin SpA ranks #32 out of 87 companies in the Medical Diagnostics & Research industry, placing it in the top 36.8%.
Is Diasorin SpA's Forward PE Ratio too high?
Diasorin SpA's current Forward PE Ratio is 18.29. The Medical Diagnostics & Research industry median Forward PE Ratio is 21.41. Diasorin SpA's value of 18.29 is 14.6% below this industry median. Based on the distribution chart, Diasorin SpA ranks #32 out of 87 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Diasorin SpA has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diasorin SpA's Forward PE Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diasorin SpA ranks #32 out of 87 companies for Forward PE Ratio. This puts Diasorin SpA in the upper half of its industry. The industry median Forward PE Ratio is 21.41. Diasorin SpA's value of 18.29 is 14.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Diagnostics & Research company?
The median Forward PE Ratio among Medical Diagnostics & Research companies is 21.41, based on 87 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diasorin SpA's current Forward PE Ratio of 18.29 is 14.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Diasorin SpA and its competitors. For the Medical Diagnostics & Research industry, the median Forward PE Ratio is 21.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diasorin SpA's current Forward PE Ratio is 18.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diasorin SpA stock overvalued right now?
Based on GuruFocus' analysis, Diasorin SpA (WBO:DIAS) is currently considered Modestly Undervalued. The stock's GF Value™ is €90.10, compared to a current price of €70.08 — trading 22.2% below its estimated fair value. The current Forward PE Ratio is 18.29 and 14.6% below the Medical Diagnostics & Research industry median of 21.41. Diasorin SpA's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Diasorin SpA (WBO:DIAS), the current Forward PE Ratio is 18.29 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diasorin SpA (WBO:DIAS) Overvalued in 2026?
Based on GuruFocus' analysis, Diasorin SpA stock appears to be undervalued.
The current stock price of €70.08 is trading 22.2% below its estimated GF Value™ of €90.10.
GuruFocus considers Diasorin SpA to be Modestly Undervalued.
Key valuation signals for WBO:DIAS:
Forward PE Ratio: 18.29
GF Value™: €90.10 vs. price of €70.08 (22.2% below fair value)
Industry Position: 14.6% below the Medical Diagnostics & Research median (#32 of 87)
No single metric tells the full story. See the WBO:DIAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diasorin develops and manufactures a broad portfolio of in vitro diagnostics for detecting pathogens and sample contamination from the human body, as well as for use in industrial settings, such as food and water contamination testing. The company operates three segments: immunodiagnostics (69% of sales), molecular diagnostics (16%), and licensed technologies (14%). Diasorin was an important manufacturer of covid tests, which boosted its profits during the pandemic, but this segment's importance has decreased over the years, and in 2025, it accounted for only 1% of total sales.
74GF Score
Get the complete analysis for WBO:DIAS
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:DIAS has been successfully added to your 